Loring Wolcott & Coolidge Fiduciary Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $41.1M | Sell |
65,875
-6,555
| -9% | -$4.46M | 0.4% | 49 |
|
|
2026
Q1 | $54.2M | Sell |
72,430
-14,545
| -17% | -$11.1M | 0.54% | 45 |
|
|
2025
Q4 | $67.1M | Sell |
86,975
-4,752
| -5% | -$3.23M | 0.61% | 38 |
|
|
2025
Q3 | $52.8M | Sell |
91,727
-8,186
| -8% | -$4.63M | 0.46% | 42 |
|
|
2025
Q2 | $52.5M | Buy |
99,913
+3,440
| +4% | +$1.92M | 0.46% | 44 |
|
|
2025
Q1 | $56.7M | Sell |
96,473
-9,618
| -9% | -$6.62M | 0.55% | 42 |
|
|
2024
Q4 | $72.6M | Sell |
106,091
-3,390
| -3% | -$2.84M | 0.62% | 37 |
|
|
2024
Q3 | $102M | Buy |
109,481
+5,801
| +6% | +$6.46M | 0.91% | 32 |
|
|
2024
Q2 | $114M | Buy |
103,680
+16,406
| +19% | +$15.9M | 1.05% | 29 |
|
|
2024
Q1 | $78.6M | Buy |
87,274
+25,828
| +42% | +$24.6M | 0.78% | 35 |
|
|
2023
Q4 | $57.9M | Buy |
61,446
+17,529
| +40% | +$14.4M | 0.57% | 41 |
|
|
2023
Q3 | $36M | Buy |
43,917
+27,181
| +162% | +$21.4M | 0.4% | 49 |
|
|
2023
Q2 | $12M | Buy |
16,736
+4,016
| +32% | +$3.1M | 0.13% | 66 |
|
|
2023
Q1 | $10.5M | Buy |
12,720
+123
| +1% | +$92.8K | 0.12% | 66 |
|
|
2022
Q4 | $9.09M | Buy |
12,597
+663
| +6% | +$489K | 0.11% | 67 |
|
|
2022
Q3 | $8.22M | Buy |
11,934
+929
| +8% | +$585K | 0.11% | 67 |
|
|
2022
Q2 | $6.5M | Buy |
11,005
+92
| +0.8% | +$59.8K | 0.08% | 76 |
|
|
2022
Q1 | $7.62M | Buy |
10,913
+71
| +0.7% | +$44.9K | 0.08% | 77 |
|
|
2021
Q4 | $6.85M | Buy |
10,842
+135
| +1% | +$83K | 0.06% | 84 |
|
|
2021
Q3 | $6.48M | Buy |
10,707
+22
| +0.2% | +$13.7K | 0.06% | 80 |
|
|
2021
Q2 | $5.97M | Buy |
10,685
+550
| +5% | +$279K | 0.06% | 81 |
|
|
2021
Q1 | $4.79M | Buy |
10,135
+9,975
| +6,234% | +$4.86M | 0.05% | 87 |
|
|
2020
Q4 | $77K | Buy |
+160
| New | +$86.4K | ﹤0.01% | 382 |
|
|
2018
Q2 | – | Sell |
-345
| Closed | -$119K | – | 719 |
|
|
2018
Q1 | $119K | Sell |
345
-400
| -54% | -$139K | ﹤0.01% | 345 |
|
|
2017
Q4 | $280K | Hold |
745
| – | – | 0.01% | 245 |
|
|
2017
Q3 | $333K | Buy |
745
+500
| +204% | +$238K | 0.01% | 231 |
|
|
2017
Q2 | $120K | Hold |
245
| – | – | ﹤0.01% | 338 |
|
|
2017
Q1 | $95K | Hold |
245
| – | – | ﹤0.01% | 356 |
|
|
2016
Q4 | $90K | Hold |
245
| – | – | ﹤0.01% | 342 |
|
|
2016
Q3 | $98K | Hold |
245
| – | – | ﹤0.01% | 336 |
|
|
2016
Q2 | $86K | Hold |
245
| – | – | ﹤0.01% | 337 |
|
|
2016
Q1 | $88K | Hold |
245
| – | – | ﹤0.01% | 324 |
|
|
2015
Q4 | $133K | Hold |
245
| – | – | ﹤0.01% | 309 |
|
|
2015
Q3 | $125K | Hold |
245
| – | – | ﹤0.01% | 331 |
|
|
2015
Q2 | $125K | Buy |
245
+60
| +32% | +$29.3K | ﹤0.01% | 331 |
|
|
2015
Q1 | $84K | Buy |
185
+85
| +85% | +$36K | ﹤0.01% | 382 |
|
|
2014
Q4 | $41K | Buy |
+100
| New | +$39.3K | ﹤0.01% | 448 |
|
Other funds holding REGN
Loring Wolcott & Coolidge Fiduciary Advisors's REGN Position: Q2 2026 in Review
Loring Wolcott & Coolidge Fiduciary Advisors reduced its Regeneron Pharmaceuticals (REGN) stake by 9.1% in Q2 2026, selling an estimated $4.46M and leaving 65,875 shares worth $41.1M. The position accounts for 0.4% of the portfolio, ranked #49.
Loring Wolcott & Coolidge Fiduciary Advisors first reported a position in REGN in Q4 2014 and has held it in 37 quarters since. The position peaked at $114M in Q2 2024. 729 funds tracked by Wall St. Rank hold REGN as of Q2 2026.
- Loring Wolcott & Coolidge Fiduciary Advisors held 65,875 shares of Regeneron Pharmaceuticals worth $41.1M as of Q2 2026.
- Loring Wolcott & Coolidge Fiduciary Advisors sold 6,555 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $4.46M.
- Regeneron Pharmaceuticals made up 0.4% of Loring Wolcott & Coolidge Fiduciary Advisors's portfolio in Q2 2026, its #49 holding.
- Loring Wolcott & Coolidge Fiduciary Advisors first reported a position in Regeneron Pharmaceuticals in Q4 2014 and has held it in 37 quarters since.
- Loring Wolcott & Coolidge Fiduciary Advisors's Regeneron Pharmaceuticals position peaked at $114M in Q2 2024.
- 729 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.
Based on Loring Wolcott & Coolidge Fiduciary Advisors's 13F filing for Q2 2026, filed 30 Jul 2026.